For the watch-and-wait group, (A) overall survival is 73% (95% CI, 60%-89%), (B) disease-free survival is 75% (95% CI, 62%-90%), and (C) disease-specific survival is 90% (95% CI, 81%-99%). In the overall survival analysis, 70% of the watch-and-wait group died of other causes. Survival was measured from the end of neoadjuvant treatment. The disease-free survival events included locoregional recurrence, distant recurrence, and death from any cause, but specifically excluded local regrowth.